



MEETING OF THE WHO
INFORMAL WORKING
GROUP ON
ECHINOCOCCOSIS
(WHO-IWGE)

WHO Headquarters
Geneva, Switzerland
15 –16 December 2016



World Health
Organization

Photos cover:

© Artor Khulan (back)

© ILO (front central)

© Adriano Casulli (front top)

MEETING OF THE WHO INFORMAL WORKING GROUP ON ECHINOCOCCOSIS (WHO-IWGE)

WHO Headquarters, Geneva, Switzerland
15–16 December 2016



WHO/HTM/NTD/NZD/2017.01

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Meeting of the WHO Informal Working Group on Echinococcosis (WHO-IWGE), Geneva, Switzerland, 15–16 December 2016. Geneva, Switzerland: World Health Organization; 2017 (WHO/HTM/NTD/NZD/2017.01). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland

CONTENTS

Executive summary.....	v
Key messages.....	v
Declarations of interest	v
1. Background and objectives.....	1
1.1 Vision of WHO	1
1.2 Meeting objectives.....	2
2. Outstanding problems in the fields of CE and AE	2
2.1 Updating current knowledge and practices	2
Box 1. EG95 vaccine	2
Box 2. Clinical management of CE	3
Box 3. Mapping of CE and AE	4
Box 4. Screening ethics	5
2.2 Dissemination of best clinical and control practices.....	6
Box 5. Ultrasound screening and training for CE: the Argentinian experience	6
2.3 Accessibility and use of best clinical and control practices	6
Box 6. Problems in benzimidazole antiparasitic treatment	6
3. Future research	8
Box 7. Is evidence from case series of patients admissible for treatment recommendations?	9
4. WHO-IWGE meeting consensus.....	9
4.1 Structure of the WHO-IWGE.....	9
4.2 Working groups	9
4.3 Aims and objectives of the WHO-IWGE: concepts of a renewed way forward	11
4.4 Deliverables	11
Box 8. Experience of TDR with databases.....	11
Box 9. The European Register of Cystic Echinococcosis (ERCE)	11
Box 10. Human cystic Echinococcosis ReseArch in Central and Eastern Societies (HERACLES)	12
Box 11. South American initiative for the surveillance, diagnosis and control of CE	12
5. References.....	13
 Annex 1.Participants	 15
Annex 2.Agenda of the meeting.....	16
Annex 3.Life cycles and points of intervention of echinococcosis.....	18

EXECUTIVE SUMMARY

The WHO Department for Control of Neglected Tropical Diseases and the newly appointed co-chairs of the WHO Informal Working Group on Echinococcosis (WHO-IWGE) convened a meeting at WHO headquarters in Geneva on 15–16 December 2016 to define the structure, participation, objectives, timelines and deliverables of the WHO-IWGE for the following two years and to renew WHO-IWGE activities.

The meeting was attended by representatives of endemic regions, with a wide range of areas of expertise and networks, who constitute the WHO-IWGE Steering Group (see Annex 1). Participants recommended that the WHO-IWGE take a problem-oriented, pragmatic approach to updating clinical and control procedures within the constraint of a tight budget and move cystic echinococcosis (CE) and alveolar echinococcosis (AE) into mainstream clinical medicine and public health, where appropriate with a One Health approach. The Steering Group will initiate, coordinate and facilitate the activities of the wider group of CE and AE experts and seek additional advice from outside the field. The Group initiated thematic working groups on clinical CE, CE control, clinical AE and AE control. Experts in these fields will be invited to participate in the working groups to prepare as a first step concise technical manuals with immediate practical application to improve the quality of patient care and infection control.

The agenda of the meeting is shown in Annex 2 and the life cycle of echinococcosis and the points at which intervention is possible in Annex 3.

KEY MESSAGES

- CE and AE differ in their transmission cycles and disease manifestations. For practical purposes, such as the production of technical manuals, clinical and control issues for the two diseases will be addressed separately.
- CE and AE should be moved into mainstream clinical medicine and public health, where appropriate with a One Health approach. Input from a broad range of disciplines in clinical medicine and public health will be instrumental in development and innovation in neglected tropical diseases.
- Tools and recommendations elaborated by the WHO-IWGE will be disseminated through national and international health policy channels and major medical and public health conferences to improve access to updated and innovative clinical and control strategies.
- The main deliverables of the coming two years are clinical and control technical manuals with immediate practical impact.

DECLARATIONS OF INTEREST

All participants completed WHO declaration of interest forms before the meeting. The forms were submitted to and reviewed by the WHO Secretariat. No conflict of interest was identified.

预览已结束，完整报告链接和二

<https://www.yunbaogao.cn/report/index/report?rep>